Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Margin on revision...

    Margin on revision knee surgery implants as high as 277 percent: NPPA

    Written by Ruby Khatun Khatun Published On 2017-08-10T11:30:12+05:30  |  Updated On 18 Aug 2021 2:55 PM IST

    New Delhi: Drug price regulator NPPA said it has found average trade margins on various knee implants used in revision surgery to be as high as 277 per cent after analysing available market data.


    The National Pharmaceutical Pricing Authority (NPPA) said it analysed trade margins in the orthopaedic knee implants used in revision surgery cases based on available data from official sources, manufacturers and importers.


    Sharing the data from the preliminary analysis on its website, the NPPA said the average total trade margin was found to be the highest in case of tibial plate at 277 per cent with MRP ranging from Rs 51,000 to Rs 1.65 lakh.


    The margin to importer for the same was 65 per cent with landing price ranging from Rs 19,506 to Rs 32,032. The margin to distributor 128 per cent with minimum and maximum price to distributor ranging from Rs 22,293 to Rs 54,000.


    The drug price regulator further found that the second highest average total trade margin was on patella at 219 per cent with MRP ranging between Rs 4,000 and Rs 20,000 although the landed price was between Rs 1,178 and Rs 5,022.


    Similarly, the average total trade margin on femoral implant was 196 per cent with MRP between Rs 74,875 and Rs 2,67,500, while the landed prices ranged between Rs 27,877 and Rs 79,433.


    The NPPA said the average total trade margin on Insert was 182 per cent priced between Rs 25,041 and Rs 57,583 whereas the landed price of the imported implant was between Rs 8,718 and Rs 18,234.


    When contacted for comments, medical devices industry body MTaI said: "This demonstrates a lack of understanding of the revision knee system and the data seems inaccurate."


    MTaI further said its members would review the NPPA data and "issue a detailed and thoughtful response".


    In a revision knee surgery, a previously used implants are replaced by new ones.


    Last week, the NPPA had invited comments from stakeholders for discussion after it found that the average trade margin on orthopaedic knee implants to be as high as 313 per cent.


    Read also: Average trade margin on knee implants as high as 313 percent: NPPA
    277 percentaverage total trade margindistributorhighimportersknee implantsmanufacturersMedical DevicesMTaINational Pharmaceutical Pricing AuthorityNPPAorthopaedicRevisionsurgerytrade margin
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok